Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 2/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4803191 | 1.00 | KCNH2 (0.38) | KCNH2NR3C1ABCB1PGRNR3C2 | |
| SCHEMBL4801282 | 0.93 | NR3C1 (0.41) | KCNH2NR3C1ABCB1PGRNR3C2 | |
| SCHEMBL4801291 | 0.93 | NR3C1 (0.41) | KCNH2NR3C1ABCB1PGRNR3C2 | |
| SCHEMBL2295690 | 0.91 | MAPT (0.37) | KCNH2NR3C1ABCB1CSF1RADRB3 | |
| SCHEMBL12380684 | 0.91 | MAPT (0.37) | KCNH2NR3C1ABCB1CSF1RADRB3 | |
| SCHEMBL2295688 | 0.91 | MAPT (0.37) | KCNH2NR3C1ABCB1CSF1RADRB3 | |
| SCHEMBL3290827 | 0.90 | KCNH2 (0.42) | KCNH2NR3C1ABCB1ARCSF1R | |
| SCHEMBL3290825 | 0.90 | KCNH2 (0.42) | KCNH2NR3C1ABCB1ARCSF1R | |
| SCHEMBL4804593 | 0.90 | KCNH2 (0.40) | KCNH2NR3C1ABCB1CSF1RADRB3 | |
| SCHEMBL4804569 | 0.90 | KCNH2 (0.40) | KCNH2NR3C1ABCB1CSF1RADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7453010-B2 | Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof | SANOFI AVENTIS (FR) | 2008-11-18 | — | — | US | disclosed |
| US-20060100283-A1 | Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100283-A1 | Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof | CHRM1, CHRM2, C1R | KCNH2 905/4885NR3C1 71/4885ABCB1 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.